- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03138603
Metoprolol to Reduce Perioperative Myocardial Injury (ORION)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All enrolled patients will be beta-blocker naïve for at least 30-days prior to their scheduled surgical procedure. Study patients will be randomly assigned to an interventional drug arm (metoprolol tartrate vs placebo-comparator). At the conclusion of anesthesia following the surgical procedure, patients hemodynamically stable and meeting study safety parameters (heart rate greater-than-65; systolic blood pressure greater-than-110) will receive 3-intravenous doses of interventional study drug (metoprolol tartrate 5mg or placebo-comparator), based on previously assigned study arm; then, patients remaining hemodynamically stable will receive an oral dose (25mg metoprolol vs placebo-comparator) approximately every 8-hours for up to 3-days during postoperative hospital admission.
From arrival in the preop holding area through up to 72 hours postoperative admission to hospital discharge or end of study treatment (whichever occurs first), patients will be continuously monitored through medical records assessments, Holter monitoring, mobile hemodynamic monitoring (VisiMobile), and in-person daily follow-up visits that include 12-lead ECG, and blood collections for serial cardiac biomarkers for high-sensitivity troponin.
Additional study patient postoperative assessment will be performed at 30 days and 1 year after surgery. These can be completed by interview and/or medical record review.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Medicine
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age >= 50 years
- Beta-blocker naïve [30 days prior to surgery]
Previously diagnosed coronary artery disease (CAD), or
- History of peripheral vascular disease (PVD), or
- Chronic kidney disease (CKD) [eGFR ≤60ml/min], or
- History of positive stress test or
- At high risk for CAD (must meet at least 2 criteria):
i. Age >= 70 years ii. Hypertension iii. Diabetes requiring oral medication or insulin iv. Current smoker or some days smoker within the past 2 years
- Major non-cardiac, elective surgery under general anesthesia
Exclusion Criteria
Subjects will not be enrolled if any of the following criteria exist:
- History of stroke, or transient ischemic attack (TIA)
- Previously diagnosed carotid disease, i.e., either 70% unilateral or 50% bilateral carotid occlusion.
- Heart rate <=55bpm
- Congestive heart failure with New York Heart Association(NYHA) Functional Classification of III-IV or left ventricular heart failure with ejection fraction ≤50%
- Severe valvular regurgitation
- Second or third degree atrioventricular (AV) block without pacemaker
- Active asthma or chronic obstructive pulmonary disease (COPD) with symptoms or resolving symptoms on day of surgery
- Anemia [HB<=9g/dL]
- Allergy to beta-blockade drugs
- Unwilling or unable to give consent for participation
- Undergoing any carotid endarterectomy, endovascular, endoscopic, superficial, or ambulatory procedures
- Pregnancy or lactating women
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metoprolol
Metoprolol group, 3-intravenous doses of 5mg metoprolol tartrate (over 15-minutes), and oral dose(s) of 25mg metoprolol approximately every 8 hours postoperatively for up to 3-days (or 72 hrs).
|
Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
Other Names:
|
Placebo Comparator: Placebo
Placebo comparator group, up-to-three intravenous doses of placebo comparator (over 15-minutes), and oral dose(s) of a placebo comparator approximately every 8 hours postoperatively for up to 3-days (or 72 hrs).
|
Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of Myocardial Injury following Post-op Beta-blocker therapy
Time Frame: Up to 72 hours following surgery
|
Measure effectiveness of post-operative beta-blocker therapy to reduce myocardial injury by monitoring daily biomarkers (High-Sensitivity cardiac Troponin [HS-cTn]). Myocardial injury is defined as a new hscTn elevation >99th percentile, or a 50% increase if the baseline hscTn is already elevated >99th percentile |
Up to 72 hours following surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Clinically Relevant Bradycardia
Time Frame: Up to 72 hours following surgery
|
Monitor cumulative events of bradycardia rate/duration time. Bradycardia is defined as low heart rate (HR < 50/min). |
Up to 72 hours following surgery
|
Monitor Post-operative Myocardial ischemia
Time Frame: Up to 72 hours following surgery
|
Post-operative cardiac monitoring via ECG to evaluate if myocardial ischemia is present. Myocardial Ischemia is defined as ST depression or elevation of ≥0.2 mV in one lead or ≥0.1 mV in two contiguous leads lasting ≥10 min |
Up to 72 hours following surgery
|
Stroke related events following surgery
Time Frame: Up to 72 hours following surgery
|
Stroke will be defined as focal or global cerebral, spinal, or retinal dysfunction of sudden onset
|
Up to 72 hours following surgery
|
Vasopressor Therapy to Regulate Symptomatic Hypotension
Time Frame: Up to 72 hours following surgery
|
Monitor vasopressor requirements for blood pressure regulation due to symptomatic hypotension. Symptomatic hypotension (systolic BP < 90 mmHg) can be determined by clinical intervention due to low blood pressure and/or patient developed clinical symptoms due to hypotension. |
Up to 72 hours following surgery
|
Recovery Progress 30-day Post-operative
Time Frame: 30-days from surgery
|
Monitor post-operative recovery 30-days following the procedure to determine if changes to medications, readmissions, or other events have occurred since hospital discharge.
|
30-days from surgery
|
Post-operative Mortality at 1-year
Time Frame: 1-Year from surgery
|
Collect 1-year post-operative mortality of study population. Measured by 'living', 'deceased', 'date of death'. |
1-Year from surgery
|
Reduction in Major Adverse Cardiac Events (MACE)
Time Frame: Up to 72 hours following surgery
|
MACE are defined as myocardial ischemia (MI), cardiac death or coronary revascularization
|
Up to 72 hours following surgery
|
Length of Post-operative Hospitalization
Time Frame: Up to 72 hours following surgery
|
Measure post-operative length of admission associated with level of care until discharge (regular floor, intensive care unit, observation unit).
|
Up to 72 hours following surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Length of participation
|
Monitor adverse events and severity associated with low blood pressure (hypotension), low heart heart (bradycardia), nausea and vomiting; or other symptoms determined 'probably', 'possibly', 'unrelated', or 'related' to the study intervention. This includes any unplanned escalation of care admissions (e.g., Intensive Care Unit [ICU]). Study patient safety is monitored by the investigators (MD) with experience in critical care anesthesia, as well as an experienced clinical research team responsible for data collection and reporting of events. |
Length of participation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Peter Nagele, MD, University of Chicago Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Heart Diseases
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Metoprolol
Other Study ID Numbers
- IRB19-1797
- 5R01HL126892 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Yonsei UniversityCompletedMitral Valvular Heart Disease
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
University College, LondonBritish Heart Foundation; Horizon 2020 - European CommissionRecruitingValvular Heart DiseaseUnited Kingdom
Clinical Trials on Metoprolol Tartrate
-
Janssen Research & Development, LLCWithdrawn
-
Xuanwu Hospital, BeijingTianjin Lerentang factoryCompletedPremature Ventricular Contraction
-
Medical College of WisconsinNorthShore University HealthSystem; Case Western Reserve UniversityCompletedMyofascial Pelvic Pain | Interstitial Cystitis/Painful Bladder SyndromeUnited States
-
Fundación Centro Nacional de Investigaciones Cardiovasculares...Fundación Mutua Madrileña; Ministerio de Sanidad, Servicios Sociales e IgualdadCompleted
-
Mylan Pharmaceuticals IncCompleted
-
Mikkel Bring ChristensenCompletedBlood Pressure | Drug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
Mylan Pharmaceuticals IncCompleted
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, United States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, Israel, South Africa, United States